A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer
Gene L Bowman1,2,3, Hiroko H Dodge2,4, Sophie Guyonnet5,6
1Department of Nutrition and Brain Health, Nestlé Institute of Health Sciences, EPFL Campus, Lausanne, Switzerland.
Introduction:
Multinutrient approaches may produce more robust effects on brain health through interactive qualities. We hypothesized that a blood-based nutritional risk index (NRI) including three biomarkers of diet quality can explain cognitive trajectories in the multidomain Alzheimer prevention trial (MAPT) over 3-years.
Methods:
The NRI included erythrocyte n-3 polyunsaturated fatty acids (n-3 PUFA 22:6n-3 and 20:5n-3), serum 25-hydroxyvitamin D, and plasma homocysteine. The NRI scores reflect the number of nutritional risk factors (0-3). The primary outcome in MAPT was a cognitive composite Z score within each participant that was fit with linear mixed-effects models.
Results:
Eighty percent had at lease one nutritional risk factor for cognitive decline (NRI ≥1: 573 of 712). Participants presenting without nutritional risk factors (NRI=0) exhibited cognitive enhancement (β = 0.03 standard units [SU]/y), whereas each NRI point increase corresponded to an incremental acceleration in rates of cognitive decline (NRI-1: β = -0.04 SU/y, P = .03; NRI-2: β = -0.08 SU/y, P < .0001; and NRI-3: β = -0.11 SU/y, P = .0008).
Discussion:
Identifying and addressing these well-established nutritional risk factors may reduce age-related cognitive decline in older adults; an observation that warrants further study.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Biological Influences on Intelligence
Bioavailability Study Design: Healthy Subjects Versus Patients


